相关实验视频

Updated: Jun 12, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

新型特里拉西克利布类似物的合成和乙胆酶抑制活性

Liubov Muzychka¹, Oksana Muzychka¹, Oleg Smolii¹

¹V.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry, of the, National Academy of Sciences of Ukraine, 1, Academician Kukhar Str, Kyiv, 02094, Ukraine.

Chemistry & biodiversity

|September 25, 2024

概括

研究人员合成了新的pyrazino[1].

科学领域:

药用化学医学化学
药理学药理学是指药理学的学科.
有机合成有机合成

背景情况:

特里拉西克利布是一种CDK4/6抑制剂,用于减轻化疗诱导的骨髓损伤.
乙胆酶 (AChE) 是胆性神经传递中的关键酶,其抑制是各种治疗策略的目标.

研究的目的:

为了合成新型的三基的结构模拟物.
为了评估这些类似物对乙胆酶的抑制活性.
为了探索pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidine支架的潜在的ACHE抑制剂.

主要方法:

开发一种有效的合成路径,用于4,7-替代的8,9-二二瑞[1',2':1,5]pyrrolo[2,3-d]pyrimidine衍生物.
合成了十三种新的trilaciclib类似物.
在体外评估合成化合物的乙胆酶抑制.

主要成果:

一系列十三种新的pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidine衍生物已经成功合成.
大多数合成的化合物都在微分子范围内表现出乙胆酶抑制.
为这种类型的化合物建立了有效的合成方法.

结论:

皮拉齐诺[1',2':1,5] 罗[2,3-d] 胺基基架是开发新型乙胆酶抑制剂的有希望的核心.
合成的类似物显示出进一步优化的潜力,以实现更高的功效.
这项研究为合理设计新的ACHE抑制剂提供了有价值的数据.

关键词:

乙烯基胆化酶是一种循环化循环化抑制剂是一种抑制剂.皮拉齐诺[1,2:1,5] 皮罗罗[2,3-d] 皮里米丁.三环化liblib 的意思

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Author Spotlight: Advancing Therapeutics to Treat Vibriosis in Humans and Aquatic Organisms

Author Spotlight: Advancing Therapeutics to Treat Vibriosis in Humans and Aquatic Organisms

Published on: May 31, 2024

相关概念视频

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...